Bio Key International INC Form 4 insider transactions
OQB
Michael DePasquale, CEO of BIO-key International, reports acquiring 139 shares of common stock through the company's Employee Stock Purchase Plan.
OQB
James David Sullivan, Chief Legal Officer, SVP Strategy & Compliance at Bio-Key International, acquired 139 shares of common stock under the company's Employee Stock Purchase Plan on December 31, 2024.
OQB
Robert J. Michel, a director at Bio-Key International, acquired 2,587 shares of common stock as compensation for board meeting attendance fees.
OQB
Emmanuel Alia, a director at Bio-Key International, acquired 2,587 shares of common stock as payment for board meeting attendance fees.
OQB
Cameron E. Williams, a director at Bio-Key International, acquired 2,587 shares of common stock as compensation for board meeting attendance fees.
OQB
Cameron E. Williams, a director at Bio-Key International, reported acquiring shares of common stock through restricted stock grants and board committee meeting attendance fees.
OQB
Robert J. Michel, a director at Bio-Key International, acquired shares of common stock through the company's 2023 Stock Incentive Plan and board committee meeting attendance fees.
OQB
Director Emmanuel Alia acquired 3,500 shares of Bio-Key International common stock on July 31, 2024, through the company's 2023 Stock Incentive Plan.
OQB
Form 4: Bio-Key International CFO Cecilia Welch Reports Acquisition of 22,500 Shares of Common Stock
Cecilia Welch, CFO of Bio-Key International, reports the acquisition of 22,500 shares of common stock granted under the company's 2023 Stock Incentive Plan.
OQB
Mira LaCous, Chief Technology Officer of Bio-Key International, acquired 9,000 shares of common stock on July 31, 2024, as part of a restricted stock grant.
OQB
Michael DePasquale, CEO of Bio-Key International, files an amendment to a previous SEC Form 4 to update the total shares and excluded holdings.
OQB
James David Sullivan, Chief Legal Officer, SVP Strategy & Compliance at Bio-Key International, reports acquisition of 22,500 shares of common stock via a restricted stock grant.
OQB
Michael DePasquale, CEO of Bio-Key International, acquired 24,000 shares of common stock on July 31, 2024, as part of a restricted stock grant.
OQB
Mira LaCous, Chief Technology Officer of Bio-Key International, acquired 139 shares of common stock under the company's Employee Stock Purchase Plan.
OQB
James David Sullivan, Chief Legal Officer, SVP Strategy & Compliance at Bio-Key International, acquired 139 shares of common stock through the company's Employee Stock Purchase Plan.
OQB
Form 4: Bio-Key International CEO Michael DePasquale Acquires Shares Under Employee Stock Purchase Plan
Michael DePasquale, CEO of Bio-Key International, acquired 139 shares of common stock under the company's Employee Stock Purchase Plan at a price of $1.394 per share.
OQB
Cameron E. Williams, a director at Bio-Key International, acquired 1,429 shares of common stock on March 27, 2024, as payment for board meeting attendance fees.
OQB
Director Emmanuel Alia receives 1,429 shares of Bio-Key International common stock on March 27, 2024, as payment for board meeting attendance fees.
OQB
Robert J. Michel, a director at Bio-Key International, acquired 1,429 shares of common stock on March 27, 2024, as payment for board meeting attendance fees.